

VCH COVID-19 Vaccine Product Reference for Mass Clinics

Primary Series Dose 1 (no previous doses)					
Population		Dose 1 Product			
Pediatric Population (5 to 11 years of age inclusive)		Pediatric Pfizer formulation (10 mcg)			
General Population (12 years of age and older)		Adult/Adolescent Pfizer* formulation (30 mcg) or Moderna			
<ul style="list-style-type: none"> The minimum age for vaccine receipt is based on age at presentation (i.e., the Pediatric Pfizer vaccine (10 mcg) may be offered to individuals on or after their 5th birthday *Pfizer is preferentially offered for those 12-29 years of age seeking a primary series dose; Moderna is preferentially recommended for those who are moderately to severely immunocompromised. Youth age 18 or younger may legally provide Mature Minor Consent (MMC) without a parent/guardian under the Infants Act. Please refer to MMC checklist to meet legal requirements. 					
Primary Series Dose 2 (1 previous dose)					
Dose 1 history	Dose 2 Product	Spacing Interval			
		Invited at	Minimum		
Pfizer Pediatric Formulation (10 mcg)	Pfizer Pediatric Formulation* (10 mcg)	8 weeks	19 days		
Pfizer Adult/Adolescent Formulation (30 mcg)	Pfizer Adult/Adolescent Formulation** (30 mcg)	8 weeks	18 days		
Moderna (100mcg)	Moderna** (100mcg)	8 weeks	21 days		
AstraZeneca or COVISHIELD	mRNA: Moderna or Pfizer Adult/Adolescent Formulation	8 weeks	28 days		
Janssen (Johnson & Johnson)	Client is complete for series - do not offer a dose 2				
Note: Mixed COVID-19 Vaccine Series: Minimum interval is based on the minimum interval of the product used for Dose 1					
*Children less than 12 years of age who commence a series with the 10 mcg formulation and have turned 12 years of age by the time the second dose is due may receive the 30 mcg formulation that is authorized for individuals aged 12 years and older to complete their primary series.					
**When the same mRNA vaccine product is not readily available, the other mRNA product is considered interchangeable and can be offered to complete vaccine series.					
Primary Series Dose 3 (for CEV Status only)					
Primary Series History	Dose 3 Product	Spacing Interval			
		Minimum			
2 doses mRNA vaccine	Moderna (100 mcg) is preferentially recommended however Pfizer can also be offered	28 days			
Booster Dose (A completed primary series and Eligible for Booster Dose)					
Primary Series History	Booster Dose Product & Dosage		Spacing Interval		
			Invited at	Minimum	
2 doses mRNA vaccine 2 doses AZ/Covishield Mixed series: 1 mRNA + 1 AZ/Covishield 1 dose Janssen*	People aged 70+ Residents of LTC, AL, IL, ALC awaiting placement	Moderna 0.5mL (100 mcg)	Pfizer 0.3 mL (30 mcg)	6 months*	8 weeks
	Those aged 18-69 years* *30-69 years: offer Moderna (50mcg) *18-29 years: preferentially offer Pfizer (30mcg)	0.25 mL (50 mcg)			
Updating Vaccination History					
Vaccine History	Product Recommendation	Minimum			
Other WHO-Approved Vaccine (e.g. Sinovac, Sinopharm-Beijing, Covaxin)	1 dose Moderna or Pfizer Adult/Adolescent Formulation	28 days			
Non-WHO approved vaccine	Begin new COVID-19 vaccine series with mRNA (Moderna or Pfizer)	28 days			
Note: Please see BCCDC World Health Organization (WHO) Emergency Use Authorization (EUA) Qualified COVID-19 Vaccines document for further guidance					